Extra-renal manifestations of complement-mediated thrombotic microangiopathies

Frontiers in Pediatrics

Volumn 2, Issue SEP, 2014, Pages

  Hofer, Johannes ^a   Rosales, Alejandra ^a   Fischer, Caroline ^a   Giner, Thomas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

AHUS; Cardiovascular complication; Complement; Extra renal TMA; Gastrointestinal complications; Neurovascular complications; TMA

Indexed keywords

EID: 84944077804     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2014.00097     Document Type: Review

References (108)

1. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 6:60. doi: 10.1186/1750-1172-6-60
2. Riedl M, Fakhouri F, Le QM, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost (2014) 40(4):444-64. doi:10.1055/s-0034-1376153
3. Boels MG, Lee DH, van den Berg BM, Dane MJ, van den Vlag J, Rabelink TJ. The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome. Eur J Intern Med (2013) 24(6):503-9. doi:10.1016/j.ejim.2012.12.016
4. Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis (2010) 56(6):1168-74. doi:10.1053/j.ajkd.2010.06.006
5. Weitz IC. Complement the hemostatic system: an intimate relationship. Thromb Res (2014) 133(Suppl 2):S117-21. doi:10.1016/S0049-3848(14)50020-5
6. Kazatchkine MD, Fearon DT, Silbert JE, Austen KF. Surface-associated heparin inhibits Zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med (1979) 150(5):1202-15. doi:10.1084/jem.150.5.1202
7. Meri S, Pangburn MK. Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun (1994) 198(1):52-9. doi:10.1006/bbrc.1994.1008
8. Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, Herbert AP, et al. Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol (2011) 18(4):463-70. doi:10.1038/nsmb.2018
9. Richards A, Buddles MR, Donne RL, Kaplan BS, Kirk E, Venning MC, et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet (2001) 68(2):485-90. doi:10.1086/318203
10. Schmidt CQ, Herbert AP, Kavanagh D, Gandy C, Fenton CJ, Blaum BS, et al. A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol (2008) 181(4):2610-9. doi:10.4049/jimmunol.181.4.2610
11. Schmidt CQ, Herbert AP, Hocking HG, Uhrin D, Barlow PN. Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol (2008) 151(1):14-24. doi:10.1111/j.1365-2249.2007.03553.x
12. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med (2013) 24(6):496-502. doi:10.1016/j.ejim.2013.05.009
13. Koscielska-Kasprzak K, Bartoszek D, Myszka M, Zabinska M, Klinger M. The complement cascade and renal disease. Arch Immunol Ther Exp (2014) 62(1):47-57. doi:10.1007/s00005-013-0254-x
14. Morgan BP. Regulation of the complement membrane attack pathway. Crit Rev Immunol (1999) 19(3):173-98. doi:10.1615/CritRevImmunol.v19.i3.10
15. Morgan BP. The complement system: an overview. Methods Mol Biol (2000) 150:1-13
16. Wurzner R, Dierich MP. Complement in human disease. Immunol Today (1997) 18(10):460-3. doi:10.1016/S0167-5699(97)01123-7
17. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 361(17):1676-87. doi:10.1056/NEJMra0902814
18. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 111(5):707-16. doi:10.1172/JCI17423
19. Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol (2014) 36(4):399-420. doi:10.1007/s00281-014-0416-x
20. Noris M, Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol (2014) 10(3):174-80. doi:10.1038/nrneph.2013.280
21. Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol (2012) 27(8):1283-91. doi:10.1007/s00467-012-2131-y
22. Neuhaus TJ, Calonder S, Leumann EP. Heterogeneity of atypical haemolytic uraemic syndromes. Arch Dis Child (1997) 76(6):518-21. doi:10.1136/adc.76.6.518
23. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 5(10):1844-59. doi:10.2215/CJN.02210310
24. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2007) 18(8):2392-400. doi:10.1681/ASN.2006080811
25. Hu H, Nagra A, Haq MR, Gilbert RD. Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement. Pediatr Nephrol (2014) 29(6):1103-6. doi:10.1007/s00467-013-2709-z
26. Koehl B, Boyer O, Biebuyck-Gouge N, Kossorotoff M, Fremeaux-Bacchi V, Boddaert N, et al. Neurological involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol (2010) 25(12):2539-42. doi:10.1007/s00467-010-1606-y
27. Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol (2011) 3:5-12. doi:10.2147/CPAA.S17904
28. Gulleroglu K, Fidan K, Hancer VS, Bayrakci U, Baskin E, Soylemezoglu O. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol (2013) 28(5):827-30. doi:10.1007/s00467-013-2416-9
29. Haghikia A, Heeren M, Bockmeyer C, Haubitz B, Gwinner W. Progressive multifocal cerebral infarction in a young kidney transplant recipient due to thrombotic microangiopathy. BMC Nephrol (2014) 15:59. doi:10.1186/1471-2369-15-59
30. Kaplan BS, Garcia CD, Chesney RW, Segar WE, Giugno K, Chem R. Peripheral gangrene complicating idiopathic and recessive hemolytic uremic syndromes. Pediatr Nephrol (2000) 14(10-11):985-9. doi:10.1007/s004670050058
31. Singla M, John E, Hidalgo G, Grewal D, Macmillan C. Moyamoya vasculopathy in a child after hemolytic uremic syndrome: a possible etiopathogenesis. Neuropediatrics (2008) 39(2):128-30. doi:10.1055/s-2008-1081458
32. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis (2010) 55(4):708-11. doi:10.1053/j.ajkd.2009.08.011
33. Vergouwen MD, Adriani KS, Roos YB, Groothoff JW, Majoie CB. Proximal cerebral artery stenosis in a patient with hemolytic uremic syndrome. AJNR Am J Neuroradiol (2008) 29(5):e34. doi:10.3174/ajnr.A0965
34. Loirat C, Macher MA, Elmaleh-Berges M, Kwon T, Deschenes G, Goodship TH, et al. Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrol Dial Transplant (2010) 25(10):3421-5. doi:10.1093/ndt/gfq319
35. Azukaitis K, Loirat C, Malina M, Adomaitiene I, Jankauskiene A. Macrovascular involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol (2014) 29(7):1273-7. doi:10.1007/s00467-013-2713-3
36. Bekassy ZD, Kristoffersson AC, Cronqvist M, Roumenina LT, Rybkine T, Vergoz L, et al. Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. Nephrol Dial Transplant (2013) 28(11):2899-907. doi:10.1093/ndt/gft340
37. Gomez-Lado C, Martinon-Torres F, Alvarez-Moreno A, Eiris-Punal J, Carreira-Sande N, Rodriguez-Nunez A, et al. Reversible posterior leukoencephalopathy syndrome: an infrequent complication in the course of haemolytic-uremic syndrome. Rev Neurol (2007) 44(8):475-8
38. Eriksson KJ, Boyd SG, Tasker RC. Acute neurology and neurophysiology of haemolytic-uraemic syndrome. Arch Dis Child (2001) 84(5):434-5. doi:10.1136/adc.84.5.434
39. Steinborn M, Leiz S, Rudisser K, Griebel M, Harder T, Hahn H. CT and MRI in haemolytic uraemic syndrome with central nervous system involvement: distribution of lesions and prognostic value of imaging findings. Pediatr Radiol (2004) 34(10):805-10. doi:10.1007/s00247-004-1289-2
40. Orth D, Wurzner R. Complement in typical hemolytic uremic syndrome. Semin Thromb Hemost (2010) 36(6):620-4. doi:10.1055/s-0030-1262883
41. Wurzner R, Riedl M, Rosales A, Orth-Holler D. Treatment of enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome (eHUS). Semin Thromb Hemost (2014) 40(4):508-16. doi:10.1055/s-0034-1375298
42. Hofer J, Giner T, Jozsi M. Complement factor h-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment. Semin Thromb Hemost (2014) 40(4):431-43. doi:10.1055/s-0034-1375297
43. Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int (2014) 85(5):1151-60. doi:10.1038/ki.2013.373
44. Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol (2010) 21(12):2180-7. doi:10.1681/ASN.2010030315
45. Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol (2013) 8(3):407-15. doi:10.2215/CJN.01260212
46. Ohanian M, Cable C, Halka K. Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report. Clin Pharmacol (2011) 3:45-50. doi:10.2147/CPAA.S23687
47. Sallee M, Daniel L, Piercecchi MD, Jaubert D, Fremeaux-Bacchi V, Berland Y, et al. Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant (2010) 25(6):2028-32. doi:10.1093/ndt/gfq160
48. Vilalta R, Lara E, Madrid A, Chocron S, Munoz M, Casquero A, et al. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol (2012) 27(12):2323-6. doi:10.1007/s00467-012-2276-8
49. Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med (2006) 3(10):e431. doi:10.1371/journal.pmed.0030431
50. Abarrategui-Garrido C, Martinez-Barricarte R, Lopez-Trascasa M, de Cordoba SR, Sanchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood (2009) 114(19):4261-71. doi:10.1182/blood-2009-05-223834
51. Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey MA, Bordereau P, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood (2012) 119(18):4182-91. doi:10.1182/blood-2011-10-383281
52. Hawkins BM, Abu-Fadel M, Vesely SK, George JN. Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion (2008) 48(2):382-92
53. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med (2003) 127(7):834-9
54. Gami AS, Hayman SR, Grande JP, Garovic VD. Incidence and prognosis of acute heart failure in the thrombotic microangiopathies. Am J Med (2005) 118(5):544-7. doi:10.1016/j.amjmed.2005.02.019
55. Abu-Arafeh I, Gray E, Youngson G, Auchterlonie I, Russell G. Myocarditis and haemolytic uraemic syndrome. Arch Dis Child (1995) 72(1):46-7. doi:10.1136/adc.72.1.46
56. Askiti V, Hendrickson K, Fish AJ, Braunlin E, Sinaiko AR. Troponin I levels in a hemolytic uremic syndrome patient with severe cardiac failure. Pediatr Nephrol (2004) 19(3):345-8. doi:10.1007/s00467-003-1343-6
57. Birk PE, Chakrabarti S, Lacson AG, Ogborn MR. Cardiac tamponade as a terminal event in the hemolytic uremic syndrome in childhood. Pediatr Nephrol (1994) 8(6):754-5. doi:10.1007/BF00869112
58. Eckart P, Guillot M, Jokic M, Maragnes P, Boudailliez B, Palcoux JB, et al. Cardiac involvement during classic hemolytic uremic syndrome. Arch Pediatr (1999) 6(4):430-3. doi:10.1016/S0929-693X(99)80226-7
59. Mohammed J, Filler G, Price A, Sharma AP. Cardiac tamponade in diarrhoea-positive haemolytic uraemic syndrome. Nephrol Dial Transplant (2009) 24(2):679-81. doi:10.1093/ndt/gfn649
60. Poulton J, Taylor CM, De Giovanni JV. Dilated cardiomyopathy associated with haemolytic uraemic syndrome. Br Heart J (1987) 57(2):181-3. doi:10.1136/hrt.57.2.181
61. Thayu M, Chandler WL, Jelacic S, Gordon CA, Rosenthal GL, Tarr PI. Cardiac ischemia during hemolytic uremic syndrome. Pediatr Nephrol (2003) 18(3):286-9
62. Thomas NJ, Messina JJ, DeBruin WJ, Carcillo JA. Cardiac failure in hemolytic uremic syndrome and rescue with extracorporeal life support. Pediatr Cardiol (2005) 26(1):104-6. doi:10.1007/s00246-004-0708-3
63. Walker AM, Benson LN, Wilson GJ, Arbus GS. Cardiomyopathy: a late complication of hemolytic uremic syndrome. Pediatr Nephrol (1997) 11(2):221-2. doi:10.1007/s004670050267
64. Le QM, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant (2013) 13(3):663-75. doi:10.1111/ajt.12077
65. Malina M, Gulati A, Bagga A, Majid MA, Simkova E, Schaefer F. Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics (2013) 131(1):e331-5. doi:10.1542/peds.2012-0903
66. Ozel A, Caliskan U, Gucer S. Peripheral gangrene complicating hemolytic uremic syndrome in a child. Pediatr Nephrol (2003) 18(5):465-7
67. Ardissino G, Tel F, Testa S, Marzano AV, Lazzari R, Salardi S, et al. Skin involvement in atypical hemolytic uremic syndrome. Am J Kidney Dis (2014) 63(4):652-5. doi:10.1053/j.ajkd.2013.09.020
68. Abdallah E, Al-Helal B, Al-Rashidi A, Asad R. ANCA negative pulmonary renal syndrome with pathologic findings of thrombotic microangiopathy. Arab J Nephrol Transplant (2013) 6(1):31-5
69. Losito A, Pittavini L, Covarelli C. Thrombotic microangiopathic nephropathy, pulmonary hypertension and nephromegaly: case report of a patient treated with endothelin receptor antagonist. Clin Nephrol (2012) 77(2):164-70. doi:10.5414/CN106829
70. Yamamoto T, Nagayama K, Satomura K, Honda T, Okada S. Increased serum IL-10 and endothelin levels in hemolytic uremic syndrome caused by Escherichia coli O157. Nephron (2000) 84(4):326-32. doi:10.1159/000045607
71. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost (2005) 31(6):681-90. doi:10.1055/s-2005-925474
72. Komhoff M, Roofthooft MT, Westra D, Teertstra TK, Losito A, van de Kar NC, et al. Combined pulmonary hypertension and renal thrombotic microangiopathy in cobalamin C deficiency. Pediatrics (2013) 132(2):e540-4. doi:10.1542/peds.2012-2581
73. Jodele S, Hirsch R, Laskin B, Davies S, Witte D, Chima R. Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Biol Blood Marrow Transplant (2013) 19(2):202-7. doi:10.1016/j.bbmt.2012.08.022
74. Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood (2013) 122(12):2003-7. doi:10.1182/blood-2013-05-501445
75. Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood (2014) 124(4):645-53. doi:10.1182/blood-2014-03-564997
76. Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant (2014) 20(4):518-25. doi:10.1016/j.bbmt.2013.12.565
77. Hofer J, Giner T, Safouh H. Diagnosis and treatment of the hemolytic uremic syndrome disease spectrum in developing regions. Semin Thromb Hemost (2014) 40(4):478-86. doi:10.1055/s-0034-1376154
78. Dierickx D, Monbaliu D, De RA, Wisanto E, Lerut E, Devos T, et al. Thrombotic microangiopathy following intestinal transplantation: a single center experience. Transplant Proc (2010) 42(1):79-81. doi:10.1016/j.transproceed.2009.12.016
79. Piscitelli D, Fiore MG, Rossi R, Casiello M, Sanguedolce F. Unusual case report of thrombotic microangiopathy of the small bowel following liver transplantation, a possible immunosuppressant-induced disease with histological and ultrastructural findings. ScientificWorldJournal (2009) 9:1031-4. doi:10.1100/tsw.2009.115
80. Aljitawi OS, Rodriguez L, Madan R, Ganguly S, Abhyankar S, McGuirk JP. Late-onset intestinal perforation in the setting of posttransplantation microangiopathy: a case report. Transplant Proc (2010) 42(9):3892-3. doi:10.1016/j.transproceed.2010.08.025
81. Fujino M, Kim Y, Ito M. Intestinal thrombotic microangiopathy induced by FK506 in rats. Bone Marrow Transplant (2007) 39(6):367-72. doi:10.1038/sj.bmt.1705588
82. Komeno Y, Ogawa S, Ishida T, Takeuchi K, Tsujino S, Kurokawa M, et al. Ischemic colitis as a manifestation of thrombotic microangiopathy following bone marrow transplantation. Intern Med (2003) 42(12):1228-32. doi:10.2169/internalmedicine.42.1228
83. Goffin L, Lolin K, Janssen F, Schurmans T, Dorchy H. Insulin-dependent diabetes mellitus as long term complication of haemolytic-uraemic syndrome. Diabetes Metab (2006) 32(3):276-8. doi:10.1016/S1262-3636(07)70280-X
84. Malleshappa P, Chaudhari AP, Aghariya M, Siddiqui A, Ranganath R, Shah AB. Thrombotic microangiopathy as a complication of recurrent pancreatitis. Ind J Nephrol (2011) 21(3):215-7. doi:10.4103/0971-4065.78073
85. Swisher KK, Doan JT, Vesely SK, Kwaan HC, Kim B, Lammle B, et al. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica (2007) 92(7):936-43. doi:10.3324/haematol.10963
86. Pena DR, Vaccarello M, Neiberger RE. Severe hemolytic uremic syndrome associated with rhabdomyolysis and insulin-dependent diabetes mellitus. Child Nephrol Urol (1991) 11(4):223-7
87. Burns JC, Berman ER, Fagre JL, Shikes RH, Lum GM. Pancreatic islet cell necrosis: association with hemolytic-uremic syndrome. J Pediatr (1982) 100(4):582-4. doi:10.1016/S0022-3476(82)80758-0
88. Andreoli SP, Bergstein JM. Acute rhabdomyolysis associated with hemolytic-uremic syndrome. J Pediatr (1983) 103(1):78-80. doi:10.1016/S0022-3476(83)80782-3
89. Micheletti MV, Lavoratti G, Gasperini S, Donati MA, Pela I. Hemolytic uremic syndrome and rhabdomyolysis in a patient with succinate coenzyme Q reductase (complex II) deficiency. Clin Nephrol (2011) 76(1):68-73. doi:10.5414/CN106681
90. Saunier P, Chretien D, Wood C, Rotig A, Bonnefont JP, Saudubray JM, et al. Cytochrome c oxidase deficiency presenting as recurrent neonatal myoglobinuria. Neuromuscul Disord (1995) 5(4):285-9. doi:10.1016/0960-8966(94)00071-G
91. Ornstein BW, Atkinson JP, Densen P. The complement system in pediatric systemic lupus erythematosus, atypical hemolytic uremic syndrome, and complocentric membranoglomerulopathies. Curr Opin Rheumatol (2012) 24(5):522-9. doi:10.1097/BOR.0b013e328356896b
92. Cohen D, Koopmans M, Kremer Hovinga IC, Berger SP, van Roos GM, Steup-Beekman GM, et al. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum (2008) 58(8):2460-9. doi:10.1002/art.23662
93. Shen Y, Chen XW, Sun CY, Dai M, Yan YC, Yang CD. Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases. Lupus (2010) 19(10):1195-203. doi:10.1177/0961203310368409
94. Sato N, Ohsawa I, Nagamachi S, Ishii M, Kusaba G, Inoshita H, et al. Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus (2011) 20(13):1378-86. doi:10.1177/0961203311415561
95. Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther (2013) 15(1):R12. doi:10.1186/ar4142
96. Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet (2011) 7(5):e1002079. doi:10.1371/journal.pgen.1002079
97. Foltyn ZA, Zipfel PF, Bokarewa MI, Sturfelt G, Jonsen A, Nilsson SC, et al. Factor H autoantibodies and deletion of complement factor H-related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Res Ther (2012) 14(4):R185. doi:10.1186/ar4016
98. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med (2002) 346(10):752-63. doi:10.1056/NEJMra002974
99. Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum (2005) 52(7):2120-4. doi:10.1002/art.21157
100. Canaud G, Kamar N, Anglicheau D, Esposito L, Rabant M, Noel LH, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant (2013) 13(8):2179-85. doi:10.1111/ajt.12319
101. Batal I, Domsic RT, Medsger TA, Bastacky S. Scleroderma renal crisis: a pathology perspective. Int J Rheumatol (2010) 2010:543704. doi:10.1155/2010/543704
102. Koga T, Yamasaki S, Nakamura H, Kawakami A, Furusu A, Taguchi T, et al. Renal thrombotic microangiopathies/thrombotic thrombocytopenic purpura in a patient with primary Sjogren's syndrome complicated with IgM monoclonal gammopathy of undetermined significance. Rheumatol Int (2013) 33(1):227-30. doi:10.1007/s00296-010-1569-0
103. Weitz IC. Atypical hemolytic uremic syndrome: the role of complement pathway gene mutation analysis. Clin Adv Hematol Oncol (2014) 12(4):266-8
104. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature (1998) 391(6667):591-4. doi:10.1038/35393
105. Roumenina LT, Radanova M, Atanasov BP, Popov KT, Kaveri SV, Lacroix-Desmazes S, et al. Heme interacts with c1q and inhibits the classical complement pathway. J Biol Chem (2011) 286(18):16459-69. doi:10.1074/jbc.M110.206136
106. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 358(11):1129-36. doi:10.1056/NEJMoa0707330
107. Hansson GK, Holm J, Kral JG. Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions. Acta Pathol Microbiol Immunol Scand A (1984) 92(6):429-35
108. Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis (1989) 9(6):802-11. doi:10.1161/01.ATV.9.6.802